Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study comparing darolutamide versus hormone therapy (goserelin, leuprorelin, triptorelin, degarelix) in men with untreated hormone-sensitive prostate cancer

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This study focuses on patients with Hormone Naive Prostate Cancer. The research compares two different treatment approaches: a new medication called darolutamide (also known as BAY 1841788) taken as oral tablets versus standard hormone therapy known as androgen deprivation therapy (ADT). The ADT medications used in the study include degarelix, leuprorelin, triptorelin, and goserelin, which are given either as injections under the skin or into muscle.

The purpose of this study is to determine if darolutamide can lower prostate-specific antigen (PSA) levels as effectively as standard hormone therapy after 24 weeks of treatment. The study will also look at how these treatments affect symptoms related to prostate cancer and monitor the safety of both treatment approaches.

During the study, patients will be randomly assigned to receive either darolutamide tablets or one of the standard hormone therapy medications. The treatment period lasts for 24 weeks, during which patients will have regular check-ups to measure PSA levels and assess their response to treatment. The study will also track any side effects and changes in quality of life that patients may experience during treatment.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial treatment assignment

    You will be randomly assigned to one of two treatment groups: either darolutamide tablets or androgen deprivation therapy (ADT).

    The treatment period will last for 24 weeks (approximately 6 months).

  2. Step 2

    Medication administration - Group 1 (Darolutamide)

    If assigned to the darolutamide group, you will take film-coated tablets by mouth.

    The tablets must be swallowed whole.

  3. Step 3

    Medication administration - Group 2 (ADT)

    If assigned to the ADT group, you will receive hormone therapy through injections.

    The medication will be administered either under the skin or into a muscle.

    The medications may include: leuprorelin, triptorelin, goserelin, or degarelix.

  4. Step 4

    Monitoring and assessments

    Your PSA levels (prostate-specific antigen, a blood test) will be measured throughout the study.

    The main assessment will occur at week 24 to measure how well the treatment is working.

    Your quality of life and any treatment-related symptoms will be evaluated using questionnaires.

    Regular safety assessments will be conducted to monitor for any side effects.

  5. Step 5

    Final evaluation

    At week 24, a final assessment will determine if your PSA levels have decreased by 80% or more compared to the start of the study.

    The study team will evaluate any changes in your symptoms and overall response to treatment.

Who can join the trial?

20 criteria

  • Must be 18 years or older
  • Must be able to swallow tablets whole
  • Must have adequate bone marrow function, including:
    • Sufficient white blood cells (neutrophil count ≥ 1.5)
    • Sufficient red blood cells (hemoglobin ≥ 10.0)
    • Sufficient platelets (≥ 100)
    • Must have normal kidney function (creatinine levels within specified limits)
    • Must have sufficient protein levels in blood (albumin > 25)
    • Must have normal liver function tests
    • Must have normal heart rhythm test (ECG)
    • Must use effective birth control during treatment and for 3 months after
    • Must be able to comply with study visits and follow-up schedule
    • Must provide written informed consent
    • Must have confirmed prostate cancer diagnosis through tissue examination
    • Must have either no spread of cancer or no more than 4 confirmed areas where cancer has spread (excluding internal organs)
    • Must have no symptoms from prostate cancer (urinary symptoms are allowed)
    • Must have normal testosterone levels (≥ 230 ng/dL)
    • Must have two PSA blood test results ≥ 2, taken at least 2 weeks apart within the past 3 months
    • Must be able to perform normal daily activities (WHO performance status 0-1)
    • If 70 years or older, must have a satisfactory health assessment score (G8 score ≥ 14)
    • Must have a life expectancy of at least 12 months

Who cannot join the trial?

14 criteria

  • Previous treatment with any androgen deprivation therapy (ADT) - medications that reduce male hormone levels
  • Previous treatment with chemotherapy for prostate cancer
  • Age below 18 years
  • Female gender (study is for male patients only)
  • Known allergies or hypersensitivity to the study medication or its components
  • Presence of metastatic disease (cancer that has spread to other parts of the body)
  • Significant heart conditions or uncontrolled high blood pressure
  • Active or chronic liver disease
  • Severe kidney problems
  • Participation in another clinical trial within 30 days before starting this study
  • Any condition that, in the opinion of the study doctor, would make participation unsafe
  • Unable to understand or sign the informed consent form
  • History of seizures or conditions that may increase seizure risk
  • Current use of medications that could interfere with the study treatment
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Darolutamide

    A medication used to treat prostate cancer. It works by blocking the effects of male hormones (androgens) in the body, which can help slow down or stop the growth of prostate cancer cells.

  • LHRH agonists

    These medications are hormone therapy drugs that reduce testosterone levels in the body. They work by initially stimulating and then suppressing the production of testosterone, which can help control prostate cancer growth.

  • LHRH antagonist

    A type of hormone therapy that works by immediately blocking the production of testosterone without the initial stimulation seen with LHRH agonists. This medication helps control prostate cancer by reducing male hormone levels in the body.

What is already known about the treatment

  • Darolutamide

    An oral medication used in the treatment of prostate cancer, specifically for hormone-naive prostate cancer patients. This drug belongs to the class of androgen receptor inhibitors that works by blocking the effects of male hormones (androgens) on prostate cancer cells at the molecular level, preventing them from stimulating cancer growth. Darolutamide is administered as oral tablets and represents a newer generation of hormone therapy that shows promising results in clinical trials, particularly in achieving PSA response rates comparable to traditional androgen deprivation therapy (ADT).

  • LHRH Agonists/Antagonists

    A class of medications used in androgen deprivation therapy (ADT) for prostate cancer treatment that work by controlling the production of testosterone. These drugs are typically administered through injections and work by either initially stimulating and then suppressing testosterone production (agonists) or directly blocking hormone production (antagonists). They represent a standard treatment approach in hormone therapy for prostate cancer and are effective in reducing PSA levels by lowering testosterone levels in the body.

Investigated diseases

Hormone Naive Prostate Cancer - A condition where prostate cancer cells have not yet been exposed to hormone therapy treatments. The cancer begins in the prostate gland and grows in response to male hormones (androgens) like testosterone. It develops when cells in the prostate start to grow uncontrollably, forming tumors within the gland. The disease is characterized by elevated levels of prostate-specific antigen (PSA) in the blood. As the condition progresses, the cancer cells continue to rely on androgens for their growth and survival.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-510840-30-00Estimated enrolment169 patientsSponsorEuropean Organisation For Research And Treatment Of Cancer

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.